Does the media refer more to CLDX or MNKD?

In the previous week, Celldex Therapeutics had 1 more articles in the media than MannKind. MarketBeat recorded 3 mentions for Celldex Therapeutics and 2 mentions for MannKind. MannKind's average media sentiment score of 1.07 beat Celldex Therapeutics' score of 0.38 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MNKD or BCRX?

In the previous week, MannKind had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 2 mentions for MannKind and 1 mentions for BioCryst Pharmaceuticals. MannKind's average media sentiment score of 1.07 beat BioCryst Pharmaceuticals' score of 0.00 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, MNKD or INVA?

Innoviva has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.49 $5.86M -$0.07 N/A Innoviva $411.33M 4.04 $271.17M $6.01 3.74

Is MNKD or INVA more profitable?

Innoviva has a net margin of 119.89% compared to MannKind's net margin of -6.63%. Innoviva's return on equity of 33.33% beat MannKind's return on equity. Company Net Margins Return on Equity Return on Assets MannKind -6.63% -11.21% -3.92% Innoviva 119.89% 33.33% 22.67%

Does the media prefer MNKD or INVA?

In the previous week, MannKind had 1 more articles in the media than Innoviva. MarketBeat recorded 2 mentions for MannKind and 1 mentions for Innoviva. MannKind's average media sentiment score of 1.07 beat Innoviva's score of 0.67 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, NVAX or MNKD?

Novavax has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $596.34M 2.52 $440.30M -$0.58 N/A MannKind $348.97M 3.49 $5.86M -$0.07 N/A

Is NVAX or MNKD more profitable?

MannKind has a net margin of -6.63% compared to Novavax's net margin of -14.73%. MannKind's return on equity of -11.21% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% MannKind -6.63% -11.21% -3.92%

Does the media refer more to NVAX or MNKD?

In the previous week, Novavax had 3 more articles in the media than MannKind. MarketBeat recorded 5 mentions for Novavax and 2 mentions for MannKind. MannKind's average media sentiment score of 1.07 beat Novavax's score of 0.33 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MNKD or ZBIO?

In the previous week, Zenas BioPharma had 1 more articles in the media than MannKind. MarketBeat recorded 3 mentions for Zenas BioPharma and 2 mentions for MannKind. Zenas BioPharma's average media sentiment score of 1.33 beat MannKind's score of 1.07 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MannKind (MNKD) Competitors

$3.94 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$3.91 -0.03 (-0.66%)

As of 06/18/2026 07:54 PM Eastern

Compare

MNKD vs. CLDX, BCRX, INVA, NVAX, and ZBIO

Should you buy MannKind stock or one of its competitors? MarketBeat compares MannKind with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MannKind include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

How does MannKind compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

MannKind has higher revenue and earnings than Celldex Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,652.88	-$258.76M	-$4.26	N/A
MannKind	$348.97M	3.49	$5.86M	-$0.07	N/A

Celldex Therapeutics currently has a consensus price target of $49.30, indicating a potential upside of 52.02%. MannKind has a consensus price target of $8.97, indicating a potential upside of 127.63%. Given MannKind's higher probable upside, analysts clearly believe MannKind is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Celldex Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
MannKind	-6.63%	-11.21%	-3.92%

In the previous week, Celldex Therapeutics had 1 more articles in the media than MannKind. MarketBeat recorded 3 mentions for Celldex Therapeutics and 2 mentions for MannKind. MannKind's average media sentiment score of 1.07 beat Celldex Therapeutics' score of 0.38 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celldex Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, MannKind has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

49.6% of MannKind shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

MannKind beats Celldex Therapeutics on 9 of the 17 factors compared between the two stocks.

How does MannKind compare to BioCryst Pharmaceuticals?

MannKind (NASDAQ:MNKD) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

49.6% of MannKind shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MannKind has a net margin of -6.63% compared to BioCryst Pharmaceuticals' net margin of -51.71%. MannKind's return on equity of -11.21% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

MannKind presently has a consensus price target of $8.97, indicating a potential upside of 127.63%. BioCryst Pharmaceuticals has a consensus price target of $20.70, indicating a potential upside of 130.26%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, MannKind had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 2 mentions for MannKind and 1 mentions for BioCryst Pharmaceuticals. MannKind's average media sentiment score of 1.07 beat BioCryst Pharmaceuticals' score of 0.00 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.49	$5.86M	-$0.07	N/A
BioCryst Pharmaceuticals	$874.84M	2.61	$263.86M	-$1.78	N/A

Summary

BioCryst Pharmaceuticals beats MannKind on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to Innoviva?

MannKind (NASDAQ:MNKD) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

MannKind has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

MannKind presently has a consensus price target of $8.97, suggesting a potential upside of 127.63%. Innoviva has a consensus price target of $36.20, suggesting a potential upside of 60.96%. Given MannKind's stronger consensus rating and higher probable upside, research analysts plainly believe MannKind is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Innoviva has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.49	$5.86M	-$0.07	N/A
Innoviva	$411.33M	4.04	$271.17M	$6.01	3.74

Innoviva has a net margin of 119.89% compared to MannKind's net margin of -6.63%. Innoviva's return on equity of 33.33% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Innoviva	119.89%	33.33%	22.67%

49.6% of MannKind shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 2.0% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, MannKind had 1 more articles in the media than Innoviva. MarketBeat recorded 2 mentions for MannKind and 1 mentions for Innoviva. MannKind's average media sentiment score of 1.07 beat Innoviva's score of 0.67 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innoviva beats MannKind on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to Novavax?

Novavax (NASDAQ:NVAX) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

In the previous week, Novavax had 3 more articles in the media than MannKind. MarketBeat recorded 5 mentions for Novavax and 2 mentions for MannKind. MannKind's average media sentiment score of 1.07 beat Novavax's score of 0.33 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market. Comparatively, MannKind has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Novavax has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$596.34M	2.52	$440.30M	-$0.58	N/A
MannKind	$348.97M	3.49	$5.86M	-$0.07	N/A

53.0% of Novavax shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 2.6% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MannKind has a net margin of -6.63% compared to Novavax's net margin of -14.73%. MannKind's return on equity of -11.21% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
MannKind	-6.63%	-11.21%	-3.92%

Novavax presently has a consensus target price of $13.00, indicating a potential upside of 42.39%. MannKind has a consensus target price of $8.97, indicating a potential upside of 127.63%. Given MannKind's stronger consensus rating and higher possible upside, analysts plainly believe MannKind is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

MannKind beats Novavax on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to Zenas BioPharma?

MannKind (NASDAQ:MNKD) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

In the previous week, Zenas BioPharma had 1 more articles in the media than MannKind. MarketBeat recorded 3 mentions for Zenas BioPharma and 2 mentions for MannKind. Zenas BioPharma's average media sentiment score of 1.33 beat MannKind's score of 1.07 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind has higher revenue and earnings than Zenas BioPharma. MannKind is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.49	$5.86M	-$0.07	N/A
Zenas BioPharma	$10M	124.87	-$377.74M	-$8.47	N/A

MannKind presently has a consensus target price of $8.97, suggesting a potential upside of 127.63%. Zenas BioPharma has a consensus target price of $44.29, suggesting a potential upside of 123.89%. Given MannKind's stronger consensus rating and higher possible upside, equities analysts plainly believe MannKind is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

49.6% of MannKind shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MannKind has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, suggesting that its share price is 171% less volatile than the broader market.

Zenas BioPharma has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Zenas BioPharma	N/A	-99.99%	-58.06%

Summary

MannKind beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

Get MannKind News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNKD vs. The Competition

Export

Metric	MannKind	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.22B	$3.41B	$6.42B	$12.59B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-56.28	19.73	24.78	24.44
Price / Sales	3.49	318.53	532.71	109.74
Price / Cash	63.67	127.84	45.07	55.09
Price / Book	-23.18	8.16	10.80	6.58
Net Income	$5.86M	$23.94M	$3.57B	$337.17M
7 Day Performance	7.65%	2.57%	0.72%	0.83%
1 Month Performance	19.03%	0.69%	0.41%	2.25%
1 Year Performance	4.51%	55.09%	29.34%	36.14%

MannKind Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNKD MannKind	3.0618 of 5 stars	$3.94 flat	$8.97 +127.6%	+4.5%	$1.22B	$348.97M	N/A	400	Positive News High Trading Volume
CLDX Celldex Therapeutics	2.0104 of 5 stars	$32.12 +2.7%	$49.30 +53.5%	+58.2%	$2.45B	$1.54M	N/A	150
BCRX BioCryst Pharmaceuticals	2.2035 of 5 stars	$9.06 +4.1%	$20.70 +128.5%	-11.0%	$2.21B	$874.84M	N/A	530
INVA Innoviva	3.9022 of 5 stars	$22.42 -1.4%	$36.20 +61.5%	+7.1%	$1.68B	$411.33M	3.73	100	News Coverage Gap Up
NVAX Novavax	1.8186 of 5 stars	$9.21 +3.7%	$12.13 +31.7%	+42.4%	$1.46B	$1.12B	N/A	1,990	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNKD) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MannKind (MNKD) Competitors

MNKD vs. CLDX, BCRX, INVA, NVAX, and ZBIO

How does MannKind compare to Celldex Therapeutics?

Summary

How does MannKind compare to BioCryst Pharmaceuticals?

Summary

How does MannKind compare to Innoviva?

Summary

How does MannKind compare to Novavax?

Summary

How does MannKind compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MannKind (MNKD) Competitors

MNKD vs. CLDX, BCRX, INVA, NVAX, and ZBIO

How does MannKind compare to Celldex Therapeutics?

Which has preferable valuation & earnings, CLDX or MNKD?

Do analysts recommend CLDX or MNKD?

Is CLDX or MNKD more profitable?

Does the media refer more to CLDX or MNKD?

Which has more volatility and risk, CLDX or MNKD?

Do insiders and institutionals have more ownership in CLDX or MNKD?

Summary

How does MannKind compare to BioCryst Pharmaceuticals?

Do institutionals & insiders have more ownership in MNKD or BCRX?

Is MNKD or BCRX more profitable?

Do analysts recommend MNKD or BCRX?

Does the media refer more to MNKD or BCRX?

Which has more risk & volatility, MNKD or BCRX?

Which has stronger earnings and valuation, MNKD or BCRX?

Summary

How does MannKind compare to Innoviva?

Which has more risk & volatility, MNKD or INVA?

Do analysts rate MNKD or INVA?

Which has higher valuation & earnings, MNKD or INVA?

Is MNKD or INVA more profitable?

Do institutionals and insiders hold more shares of MNKD or INVA?

Does the media prefer MNKD or INVA?

Summary

How does MannKind compare to Novavax?

Does the media refer more to NVAX or MNKD?

Which has more volatility & risk, NVAX or MNKD?

Which has higher valuation and earnings, NVAX or MNKD?

Do institutionals & insiders have more ownership in NVAX or MNKD?

Is NVAX or MNKD more profitable?

Do analysts recommend NVAX or MNKD?

Summary

How does MannKind compare to Zenas BioPharma?

Does the media refer more to MNKD or ZBIO?

Which has preferable valuation and earnings, MNKD or ZBIO?

Do analysts recommend MNKD or ZBIO?

Do institutionals and insiders hold more shares of MNKD or ZBIO?

Which has more volatility and risk, MNKD or ZBIO?

Is MNKD or ZBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools